Anifrolumab in systemic lupus erythematosus: a profile of its use

AbstractAnifrolumab (Saphnelo ™), an intravenously administered immunoglobulin G1 kappa monoclonal antibody targeting the type 1 interferon alpha receptor, is effective and generally well tolerated as an add-on to standard therapy in adults with moderate to severe systemic lupus erythematosus (SLE). Anifrolumab reduces overall disease activity in patients with moderate to severe SLE despite receiving stable standard-of-care treatment, based on the totality of evidence from randomized, double-blind, placebo-controlled, phase 2b and 3 clinical trials. Anifrolumab also has corticosteroid-sparing effects and reduces skin dis ease severity. Therapeutic benefits of anifrolumab appear to be sustained over longer-term treatment. With respect to tolerability, anifrolumab recipients are at increased risk of infections (including herpes zoster). Additional long-term data are being collected in an ongoing extension of the phase 3 trials.

Source: Drugs and Therapy Perspectives - July 13, 2022 Category: Drugs & Pharmacology Source Type: research